Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

Nature

Volumn 477, Issue 7365, 2011, Pages 477-481

  Choi, Jang Hyun ^a   Banks, Alexander S ^a   Kamenecka, Theodore M ^b   Busby, Scott A ^b   Chalmers, Michael J ^b   Kumar, Naresh ^b   Kuruvilla, Dana S ^b   Shin, Youseung ^b   He, Yuanjun ^b   Bruning, John B ^c   Marciano, David P ^b   Cameron, Michael D ^b   Laznik, Dina ^a   Jurczak, Michael J ^d   Schürer, Stephan C ^e   Vidović, Dušica ^e   Shulman, Gerald I ^d   Spiegelman, Bruce M ^a   Griffin, Patrick R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' [[5 [[1 (4 NITROPHENYL)ETHYL]CARBAMOYL] 1H INDOL 1 YL]METHYL][1,19BIPHENYL] 2 CARBOXYLIC ACID; ANTIDIABETIC AGENT; CYCLIN DEPENDENT KINASE 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; SR 1664; UNCLASSIFIED DRUG;

BIOCHEMISTRY; DRUG; DRUG DEVELOPMENT; GENE EXPRESSION; HORMONE; LIGAND; MOLECULAR ANALYSIS; PHOSPHATE; PROTEIN; RODENT; WEIGHT;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG PROTEIN BINDING; FLUID RETENTION; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OSSIFICATION; PHOSPHORYLATION; PRIORITY JOURNAL; WEIGHT GAIN;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; BIPHENYL COMPOUNDS; BODY FLUIDS; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN-DEPENDENT KINASE 5; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MODELS, MOLECULAR; OBESITY; OSTEOGENESIS; PHOSPHORYLATION; PHOSPHOSERINE; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

MUS;

EID: 80053131732     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10383     Document Type: Article

References (29)

1. Lehmann, J. M., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor c (PPARc). J. Biol. Chem. 270, 12953-12956 (1995).
2. Choi, J. H., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5. Nature 466, 451-456 (2010).
3. Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARc2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
4. Willson, T. M., Lambert, M. H. & Kliewer, S. A. Peroxisome proliferator-activated receptor gamma andmetabolic disease.Annu. Rev. Biochem. 70,341-367(2001). (Pubitemid 32662214)
5. Forman, B. M., et al. 15-Deoxy-D12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARc. Cell 83, 803-812 (1995). (Pubitemid 3006324)
6. Henke, B. R., et al.N-(2-Benzoylphenyl)-L-tyrosinePPARc agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41, 5020-5036 (1998).
7. Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R., Lee, T. R. & Fonseca, V. A. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134, 61-71 (2001). (Pubitemid 32037344)
8. Kahn, S. E., et al. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care 31, 845-851 (2008).
9. Nesto, R. W., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27, 256-263 (2004). (Pubitemid 38196741)
10. Rocchi, S., et al. A unique PPARc ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8, 737-747 (2001). (Pubitemid 33030208)
11. Berger, J. P., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein c selective modulator. Mol. Endocrinol. 17, 662-676 (2003). (Pubitemid 36403578)
12. Lamotte, Y., et al. Synthesis and biological activities of novel indole derivatives as potent and selective PPARc modulators. Bioorg. Med. Chem. Lett. 20, 1399-1404 (2010).
13. Grana, X., et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc. Natl Acad. Sci. USA 91, 3834-3838 (1994). (Pubitemid 24139526)
14. Kliewer, S. A., et al. A prostaglandin J2 metabolite binds peroxisome proliferatoractivated receptor c and promotes adipocyte differentiation. Cell 83, 813-819 (1995). (Pubitemid 3006325)
15. Chawla, A., Schwarz, E. J., Dimaculangan, D. D. & Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135, 798-800 (1994). (Pubitemid 24241266)
16. Grey, A., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92, 1305-1310 (2007). (Pubitemid 46556402)
17. Lecka-Czernik, B., et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARc2. J. Cell. Biochem. 74, 357-371 (1999). (Pubitemid 29344887)
18. Bruning, J. B., et al. Partial agonists activate PPARc using a helix 12 independent mechanism. Structure 15, 1258-1271 (2007). (Pubitemid 47539157)
19. Hamuro, Y., et al. Hydrogen/deuterium-exchange (H/D-Ex) of PPARc LBD in the presence of various modulators. Protein Sci. 15, 1883-1892 (2006). (Pubitemid 44141506)
20. Nolte, R. T., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-c. Nature 395, 137-143 (1998). (Pubitemid 28425645)
21. Chalmers, M. J., Busby,S. A., Pascal, B. D., Southern, M. R.&Griffin, P. R.A two-stage differential hydrogen deuterium exchange method for the rapid characterization of protein/ligand interactions. J. Biomol. Tech. 18, 194-204 (2007).
22. DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214-E223 (1979). (Pubitemid 9249478)
23. Flier, J. S., Cook, K. S., Usher, P. & Spiegelman, B. M. Severely impaired adipsin expression in genetic and acquired obesity. Science 237, 405-408 (1987).
24. Hu, E., Liang, P. & Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271, 10697-10703 (1996). (Pubitemid 26145805)
25. Kahn, B. B. & McGraw, T. E. Rosiglitazone, PPARc, and type 2 diabetes. N. Engl. J. Med. 363, 2667-2669 (2010).
26. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193 (1994). (Pubitemid 24331336)
27. Hamuro, Y., et al. Hydrogen/deuterium-exchange (H/D-Ex) of PPARc LBD in the presence of various modulators. Protein Sci. 15, 1883-1892 (2006). (Pubitemid 44141506)
28. Mayerson, A. B., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802 (2002). (Pubitemid 34760191)
29. Kim, H. J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067 (2004).